• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.

作者信息

Cannon Christopher P, Perkovic Vlado, Agarwal Rajiv, Baldassarre James, Bakris George, Charytan David M, de Zeeuw Dick, Edwards Robert, Greene Tom, Heerspink Hiddo J L, Jardine Meg J, Levin Adeera, Li Jing-Wei, Neal Bruce, Pollock Carol, Wheeler David C, Zhang Hong, Zinman Bernard, Mahaffey Kenneth W

机构信息

Cardiovascular Division, Brigham & Women's Hospital and Baim Institute for Clinical Research, Boston, MA (C.P.C.).

The George Institute for Global Health, UNSW Sydney, Australia (V.P., H.J.L.H, M.J.J., J.-W.L., B.N.).

出版信息

Circulation. 2020 Feb 4;141(5):407-410. doi: 10.1161/CIRCULATIONAHA.119.044359. Epub 2019 Nov 11.

DOI:10.1161/CIRCULATIONAHA.119.044359
PMID:31707795
Abstract
摘要

相似文献

1
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.根据基线糖化血红蛋白评估卡格列净对2型糖尿病合并慢性肾脏病患者心血管和肾脏事件的影响，包括糖化血红蛋白<7%的患者：CREDENCE试验结果
Circulation. 2020 Feb 4;141(5):407-410. doi: 10.1161/CIRCULATIONAHA.119.044359. Epub 2019 Nov 11.
2
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.血糖控制及坎格列净降低白蛋白尿和 eGFR 的效果：CREDENCE 试验的事后分析。
Clin J Am Soc Nephrol. 2023 Jun 1;18(6):748-758. doi: 10.2215/CJN.0000000000000161. Epub 2023 Mar 31.
3
Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病合并慢性肾脏病患者中的肾脏和心血管影响：基于卡格列净和糖尿病肾脏疾病进展的临床评估试验结果的观点。
Am J Nephrol. 2020;51(4):276-288. doi: 10.1159/000506533. Epub 2020 Mar 13.
4
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.卡格列净对合并或不合并外周动脉疾病的慢性肾脏病患者心血管和肾脏事件的影响：CANVAS项目和CREDENCE试验的综合分析
Diabetes Obes Metab. 2023 Jul;25(7):2043-2047. doi: 10.1111/dom.15065. Epub 2023 Apr 24.
5
Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.糖尿病：钠-葡萄糖协同转运蛋白2抑制剂对心血管和肾脏的益处：来自CANVAS研究的见解
Nat Rev Nephrol. 2017 Sep;13(9):517-518. doi: 10.1038/nrneph.2017.113. Epub 2017 Aug 7.
6
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.卡格列净在2型糖尿病合并3期肾病患者中的疗效和安全性。
Am J Nephrol. 2014;40(1):64-74. doi: 10.1159/000364909. Epub 2014 Jul 17.
7
Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂卡格列净对日本 2 型糖尿病患者肝功能的影响：临床试验的汇总和亚组分析。
J Gastroenterol. 2018 Jan;53(1):140-151. doi: 10.1007/s00535-017-1364-8. Epub 2017 Jul 1.
8
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.根据基线肾功能评估坎格列净的心血管和肾脏结局。
Circulation. 2018 Oct 9;138(15):1537-1550. doi: 10.1161/CIRCULATIONAHA.118.035901.
9
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.卡格列净对比非奈利酮对心肾结局的影响：FIDELIO-DKD 探索性事后分析与 CREDENCE 研究结果的比较。
Nephrol Dial Transplant. 2022 Jun 23;37(7):1261-1269. doi: 10.1093/ndt/gfab336.
10
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.2型糖尿病合并慢性肾脏病患者中SGLT2抑制剂的药代动力学、药效学及临床应用
Clin Pharmacokinet. 2015 Jul;54(7):691-708. doi: 10.1007/s40262-015-0264-4.

引用本文的文献

1
Safety and efficacy of adjuvant Sotagliflozin therapy in patients with T1D - an update and systematic review and meta-analysis.索格列净辅助治疗1型糖尿病患者的安全性和有效性——最新进展及系统评价与荟萃分析
Front Endocrinol (Lausanne). 2025 Jun 3;16:1506652. doi: 10.3389/fendo.2025.1506652. eCollection 2025.
2
SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts.SGLT2抑制作用改变健康和衰竭大鼠心脏中的底物利用及线粒体氧化还原状态。
J Clin Invest. 2024 Dec 16;134(24):e176708. doi: 10.1172/JCI176708.
3
Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes.
SGLT2 抑制通过重新平衡线粒体相关内质网膜保护糖尿病肾病中的足细胞。
Cell Commun Signal. 2024 Nov 7;22(1):534. doi: 10.1186/s12964-024-01914-1.
4
The effect of empagliflozin on circulating endothelial progenitor cells in patients with diabetes and stable coronary artery disease.恩格列净对合并稳定型冠状动脉疾病的糖尿病患者循环内皮祖细胞的影响。
Cardiovasc Diabetol. 2024 Oct 28;23(1):386. doi: 10.1186/s12933-024-02466-x.
5
Sodium-glucose Co-transporter 2 Inhibitors in Acute Heart Failure: A Review of the Available Evidence and Practical Guidance on Clinical Use.急性心力衰竭中钠-葡萄糖协同转运蛋白2抑制剂：现有证据综述及临床应用实用指南
Rev Cardiovasc Med. 2022 Apr 11;23(4):139. doi: 10.31083/j.rcm2304139. eCollection 2022 Apr.
6
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂用于慢性肾脏病和糖尿病患者。
Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
7
Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases.格列净类药物在非糖尿病实验性心血管疾病治疗中的应用。
Physiol Res. 2024 Apr 18;73(Suppl 1):S377-S387. doi: 10.33549/physiolres.935364.
8
Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice.在糖尿病前期小鼠中，慢性恩格列净导致的肾脏细胞代谢、结构和功能的新生变化。
Am J Physiol Cell Physiol. 2024 Apr 1;326(4):C1272-C1290. doi: 10.1152/ajpcell.00446.2023. Epub 2024 Mar 4.
9
The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review.钠-葡萄糖共转运蛋白 2 抑制剂在冠状动脉血运重建中的应用：我们现在在哪里？系统评价。
Am J Cardiovasc Drugs. 2024 Jan;24(1):55-69. doi: 10.1007/s40256-023-00618-0. Epub 2023 Nov 17.
10
Soluble tumor necrosis factor receptor type 1 predicts cardiorenal outcomes and better associated with distinct cardiovascular or renal outcomes than precedential renal or cardiovascular events in type 2 diabetes mellitus.可溶性肿瘤坏死因子受体1可预测心脏和肾脏结局，且与2型糖尿病患者不同的心血管或肾脏结局的相关性比既往肾脏或心血管事件更强。
Ther Adv Endocrinol Metab. 2023 Oct 29;14:20420188231207345. doi: 10.1177/20420188231207345. eCollection 2023.